Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Open-Label Clinical Trial of CPI-613 in Combination With Modified FOLFIRINOX in Patients With Locally Advanced Pancreatic Cancer and Good Performance Status

NCT03374852 is registered in ClinicalTrials.gov with Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University as lead sponsor.

NCT NCT03374852
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03374852 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Open-Label Clinical Trial of CPI-613 in Combination With Modified FOLFIRINOX in Patients With Locally Advanced Pancreatic Cancer and Good Performance Status
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Phase
Phase 2
Overall status
Withdrawn
Start date
August 31, 2018
Completion date
October 31, 2020
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic ductal adenocarcinoma